Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome.

Next Previous
Trial Profile

Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clobazam (Primary)
  • Indications Lennox-Gastaut syndrome
  • Focus Therapeutic Use
  • Sponsors Lundbeck Inc

Most Recent Events

  • 28 Sep 2016 Results of post-hoc analysis from OV-1004 and OV-1012 studies (n=200) published in the Neurology.
  • 28 Sep 2016 According to Lundbeck A/S media release, Barry Gidal, PharmD, University of Wisconsin School of Pharmacy & Dept. of Neurology is the lead investigator of the post-hoc analyses
  • 21 Apr 2016 Results of a post hoc analysis presented at the 68th Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top